article thumbnail

Madrigal wins FDA approval of first drug for MASH

BioPharma Drive: Drug Pricing

Rezdiffra’s clearance is a turning point in the fight against the liver disease. But its sales potential is unclear, and competition could emerge from popular weight loss drugs.

article thumbnail

FDA Approved Oncology Drugs 2023

Crown Bioscience

In a significant development, the US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 55 new drugs in 2023. This marks the second-highest count in the past 30 years, with the highest being 59 new drug approvals in 2018 and represents an impressive 50% increase in drugs approved in 2022.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Approves Updated COVID Shots for Fall

Drugs.com

22, 2024 -- Updated shots to shield against COVID-19 infection were approved by the U.S. Food and Drug Administration on Thursday.This year's approval for the updated mRNA vaccines comes much sooner than happened in 2023, when fall. THURSDAY, Aug.

article thumbnail

FDA Approves New COVID Booster Shots

Drugs.com

MONDAY, Sept. 11, 2023 -- The U.S. Food and Drug Administration on Monday gave the green light to new COVID boosters for Americans, setting the stage for the updated vaccines to become available within days. The COVID-19 shots from Pfizer and.

article thumbnail

BioMarin finally secures FDA approval of hemophilia gene therapy

BioPharma Drive: Drug Pricing

After a prolonged journey, the medicine, known as Roctavian, is now cleared for certain patients with hemophilia A, the more common form of the rare bleeding disorder.

article thumbnail

FDA approves updated COVID boosters from Pfizer, Moderna

BioPharma Drive: Drug Pricing

Pfizer and Moderna, which have seen slowing demand for their coronavirus vaccines, expect to make the reformulated shots available in the U.S. in the coming days.

article thumbnail

FDA approves Ascendis drug for rare endocrine condition

BioPharma Drive: Drug Pricing

The clearance of Yorvipath for hypoparathyroidism was some time coming for Ascendis, which had resubmitted after receiving a rejection last year.